UCBJY News and Press, UCB S.A. ADR From 11/08/22

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022 PR Newswire Late-breaking 52-week data on investigational bimekizumab in the treatment of adults with active psoriatic arthritis and active axial spondy...

UCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONS PR Newswire UCB's Atlanta Warehouse is the first dually certified WELL Platinum and LEED Gold pharmaceutical project in the world and the first WELL Platinum building in G...

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting PR Newswire Results presented across UCB's generalized myasthenia gravis (gMG) development program builds the body of evidence around the complexities of gMG Presentations to inc...

New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis PR Newswire Three-year data from the BE BRIGHT open-label extension study are being presented at the 31st EADV Congress Over eight out ...

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress PR Newswire 20 abstracts highlight research in key disease areas including psoriasis and psoriatic arthritis New three-year data to be presented on bimekizumab in the treatment ...

The U.S. Food and Drug Administration granted orphan drug designation to UCB's (OTCPK:UCBJY) (OTCPK:UCBJF) fenfluramine hydrochloride to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. CDKL5 deficiency disorder is a rare developmental epileptic ...

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022 PR Newswire New data from BE MOBILE 1 and BE MOBILE 2 show that bimekizumab achieved consistent improvements versus placebo in signs and s...

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022 PR Newswire First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriat...

Amid the biotech bear market, there are companies that are trading on a deep bargain, yet you should be extremely careful before averaging down. Though I noticed the fundamental changes in Galapagos, I gave the company a year to turn around. Here, I presented to you three differen...

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis PR Newswire Phase 3 RAISE and MycarinG studies in generalized myasthenia gravis (gMG) show zilucoplan and rozanolixizumab improve gMG-specific outcomes with con...